Compare BLD & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | EXEL |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 11.4B |
| IPO Year | 2015 | 2000 |
| Metric | BLD | EXEL |
|---|---|---|
| Price | $407.60 | $51.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $444.33 | $46.50 |
| AVG Volume (30 Days) | 642.5K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | ★ 3.73 | 0.79 |
| Revenue | ★ $2,384,249,000.00 | $452,477,000.00 |
| Revenue This Year | $13.36 | $13.61 |
| Revenue Next Year | $4.27 | $13.13 |
| P/E Ratio | $109.13 | ★ $61.44 |
| Revenue Growth | ★ 25.07 | N/A |
| 52 Week Low | $287.50 | $33.76 |
| 52 Week High | $559.47 | $52.96 |
| Indicator | BLD | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 60.52 |
| Support Level | $392.44 | $40.17 |
| Resistance Level | $442.29 | $51.63 |
| Average True Range (ATR) | 10.35 | 1.56 |
| MACD | -0.94 | -0.12 |
| Stochastic Oscillator | 41.75 | 70.35 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments are: Installation Services and Specialty Distribution. The Installation Services segment, which generates maximum revenue, installs insulation, commercial roofing, and other building products like glass and windows, rain gutters, doors, etc, mainly in the residential new construction market. The Specialty Distribution segment distributes building and mechanical insulation, insulation accessories, and other building product materials for the residential, commercial, and industrial markets. In addition to insulation and accessories, it distributes rain gutters, closet shelving, roofing materials, and other items. Geographically, the firm mainly operates in the U.S. and, to a lesser extent, in Canada.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.